Additional file 2 of Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer
-
- Yu, Namhee
- 作成者
-
- Hwang, Mihwa
- 作成者
-
- Lee, Youngjoo
- 作成者
-
- Song, Bo Ram
- 作成者
-
- Kang, Eun Hye
- 作成者
-
- Sim, Hanna
- 作成者
-
- Ahn, Beung-Chul
- 作成者
-
- Hwang, Kum Hui
- 作成者
-
- Kim, Jihyun
- 作成者
-
- Hong, Sehwa
- 作成者
-
- Kim, Sunshin
- 作成者
-
- Park, Charny
- 作成者
-
- Han, Ji-Youn
- 作成者
メタデータ
- 公開日
- 2023-01-01
- DOI
-
- 10.6084/m9.figshare.22600913
- 10.6084/m9.figshare.22600913.v1
- 公開者
- figshare
- データ作成者 (e-Rad)
-
- Yu, Namhee
- Hwang, Mihwa
- Lee, Youngjoo
- Song, Bo Ram
- Kang, Eun Hye
- Sim, Hanna
- Ahn, Beung-Chul
- Hwang, Kum Hui
- Kim, Jihyun
- Hong, Sehwa
- Kim, Sunshin
- Park, Charny
- Han, Ji-Youn
説明
Additional file 2: Table S1. Clinical information and molecular subtypes of 102 lung cancer patients used to obtain PDCs. Table S2. The 48 drugs employed in the screening panel. We refer to the chemical or generic name of the drugs, and the target and class for each drug were classified. Table S3. Differentially expressed gene sets for the four molecular subtypes. Table S4. GSEA results (P < 0.1) using drug-associated gene signatures extracted with a machine-learning approach. Table S5. GSEA results (P < 0.1) acquired from analysis of the upregulated DEGs from four EGFR-TKI treatment groups. Table S6. EGFR-TKI resistance pathway and related gene sets.